1、COVID-19 Proteins
2、Therapeutic Fusion Protein Platform
3、mAb de novo sequencing in two weeks.

1. COVID-19 Proteins       2020-05-26

ProtTech has developed recombinant COVID-19 (SARS-COV-2) nucleocapsid protein (N Protein) used for COVID-19 research and development. [ More]

2. Therapeutic Fusion Protein Platform       2018-01-23

ProtTech has developed a novel fusion protein platform, with a series of signaling molecule-P50 fusion proteins that have potential therapeutic use (Patent Pending).  [More]

3. mAb de novo sequencing in two weeks.       2011-10-03

ProtTech has developed a new technology to determine the complete amino acid sequence of monoclonal antibodies. Due to its large size and its vast diversity in antibody sequences, it used to be an extremely difficult task to carry out the de novo sequencing of such a large protein. Recently, with the breakthrough we achieved, we are capable to determine the complete sequence of a mAb with as low as 100 ug sample of some moderate purity (>85%). ProtTech has started to provide monoclonal antibody de novo sequencing service based on this new technology. [More]